Company Overview
Abeona Therapeutics is focused on developing and delivering gene therapy products for severe and life-threatening rare diseases. Developing therapies for rare disease requires new approaches and strong collaboration between researchers, industry, regulators and patient groups. Abeona was forged from the company’s close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases such as Epidermolysis Bullosa, Sanfilippo syndrome, Batten disease, and other rare disorders.

Abeona Therapeutics Treats First Patient in Second Cohort of Phase 1/2 Clinical Trial for ABO-101 in Sanfilippo Syndrome Type B (MPS IIIB)
May 14 2019, 8:00 AM EDT

Abeona Therapeutics Reports First Quarter 2019 Financial Results and Business Highlights
May 10 2019, 4:15 PM EDT

Abeona Therapeutics Announces Presentation of EB-101 Data at Society for Investigative Dermatology Annual Meeting
May 8 2019, 8:30 AM EDT

Stock Overview
Symbol: ABEO
Exchange: Nasdaq
Market Cap: 360.85m
Last Price: $7.34
52-Week: $6.259 - $19.15

Investor Relations
Sofia Warner
Director, Investor Relations
T: +1 (646) 813-4710
swarner@abeonatherapeutics.com

5/20/2019 04:00 PM EDT

Disclaimer
Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company’s SEC reports, including but not limited to its annual reports on form 10-K and it’s quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.